Prioritizing therapeutic targets using patient-derived xenograft models
- Author(s)
- Lodhia, KA; Hadley, AM; Haluska, P; Scott, CL;
- Details
- Publication Year 2015-03-14,Volume 1855,Issue #2,Page 223-234
- Journal Title
- Biochim Biophys Acta
- Publication Type
- Journal Article
- Abstract
- Effective systemic treatment of cancer relies on the delivery of agents with optimal therapeutic potential. The molecular age of medicine has provided genomic tools that can identify a large number of potential therapeutic targets in individual patients, heralding the promise of personalized treatment. However, determining which potential targets actually drive tumor growth and should be prioritized for therapy is challenging. Indeed, reliable molecular matches of target and therapeutic agent have been stringently validated in the clinic for only a small number of targets. Patient-derived xenografts (PDXs) are tumor models developed in immunocompromised mice using tumor procured directly from the patient. As patient surrogates, PDX models represent a powerful tool for addressing individualized therapy. Challenges include humanizing the immune system of PDX models and ensuring high quality molecular annotation, in order to maximize insights for the clinic. Importantly, PDX can be sampled repeatedly and in parallel, to reveal clonal evolution, which may predict mechanisms of drug resistance and inform therapeutic strategy design.
- Publisher
- Elsevier
- Research Division(s)
- Stem Cells And Cancer
- PubMed ID
- 25783201
- Link To PubMed Central Version
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433556/
- Publisher's Version
- https://doi.org/10.1016/j.bbcan.2015.03.002
- NHMRC Grants
- NHMRC/1062702, NHMRC/1076048,
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2015-05-20 10:11:24
Last Modified: 2016-04-20 11:36:56